Shukui Qin

Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable HCC Shukui Qin, MD, PhD; Masatoshi Kudo, MD, PhD; Tim Meyer, MD, PhD; Yuxian Bai, MD; Yabing Guo, MD, PhD; Zhiqiang Meng, MD, PhD; Taroh Satoh, MD, PhD; Donatella Marino, MD; Eric Assenat, MD, PhD; Songzi Li, PhD; Yaxi Chen, MD; Frederic Boisserie, MSc; Ramil Abdrashitov, MD, PhD; Richard S. Finn, MD; Arndt Vogel, MD; Andrew X.

Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma—Reply In Reply I thank and have provided responses to Sun et al for their comments on our article1 that compared tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma. The noninferiority margin of 1.08 is clearly clinically justifiable.

Key Points Question How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically higher and more durable objective responses than sorafenib.